<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS96410</article-id>
<article-id pub-id-type="doi">10.1101/2020.09.25.313510</article-id>
<article-id pub-id-type="archive">PPR218995</article-id>
<article-version article-version-type="publisher-id">3</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Meta-analysis of MERS, SARS and COVID-19 <italic>in vitro</italic> Infection Datasets Reveals Common Patterns in Gene and Protein Expression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Martinelli</surname>
<given-names>Axel</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Akhmedov</surname>
<given-names>Murodzhon</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwee</surname>
<given-names>Ivo</given-names>
</name>
</contrib>
<aff id="A1">BigOmics Analytics, 6500 Bellinzona, Switzerland</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">
<label>*</label>correspondence: <email>axel.martinelli@bigomics.ch</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>25</day>
<month>09</month>
<year>2020</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Three lethal lower respiratory tract coronavirus epidemics have occurred over the past 20 years. This coincided with major developments in genome-wide gene and protein expression analysis, resulting in a wealth of datasets in the public domain. Seven such <italic>in vitro</italic> studies were selected for comparative bioinformatic analysis through the VirOmics Playground, a visualisation and exploration platform we developed. Despite the heterogeneous nature of the data sets, several commonalities could be observed across studies and species. Differences, on the other hand, reflected not only variations between species, but also other experimental variables, such as cell lines used for the experiments, infection protocols and viral strains. The datasets analysed here are available online through our platform (<ext-link ext-link-type="uri" xlink:href="https://public.bigomics.ch/app/omicsplayground_viromics">https://public.bigomics.ch/app/omicsplayground_viromics</ext-link>).</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Common human Coronavirus species, of which four are currently known, are usually associated with infections of the upper respiratory tract and cold-like symptoms [<xref ref-type="bibr" rid="R1">1</xref>]. However, the emergence of species infecting the lower respiratory tract and causing lethal epidemics has been a recurring event for the past 20 years. Starting with the SARS epidemic in China in 2002, the MERS epidemic in the Middle East ten years later and finally to the current COVID-19 pandemic [<xref ref-type="bibr" rid="R2">2</xref>].</p>
<p id="P3">The causative agents are all single-stranded RNA viruses (MERS-CoV for MERS, SARS-CoV-1 for SARS and SARS-CoV-2 for COVID-19) belonging to the beta-coronavirus genus within the Coronaviridae family [<xref ref-type="bibr" rid="R3">3</xref>]. All three infections started as zoonotic diseases and while the animal reservoir for both SARS-CoV-1 and MERS-CoV have been discovered, there is still uncertainty concerning the animal host for SARS-CoV-2, although it is most closely related to a bat SARS-like coronavirus [<xref ref-type="bibr" rid="R4">4</xref>]. SARS-CoV-1 and SARS-CoV-2 are, as the name implies, also genetically closer to each other than to MERS-CoV. This is reflected in the receptors that are recognised by the viral spikes surface glycoproteins of each virus. Thus, while MERS-CoV binds to dipeptidyl peptidase 4 (DPP4) on the surface of host cells [<xref ref-type="bibr" rid="R5">5</xref>], both SARS-CoV-1 and SARS-CoV-2 use the Angiotensin-converting enzyme 2 (ACE2) as the main entry point into the cell [<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. Binding to ACE2 is induced by the priming of the viral S protein via the human serine protease TMPRSS2 [<xref ref-type="bibr" rid="R7">7</xref>]. A study on mice showed that SARS-CoV-1 infections resulted in the reduction of ACE2 expression <italic>in vivo</italic> [<xref ref-type="bibr" rid="R8">8</xref>], which was postulated to be responsible for several of the pathologies induced by the infection.</p>
<p id="P4">The epidemiologies of the three diseases display different characteristics. While MERS was a highly lethal infection with a low reproductive rate, both SARS and COVID-19 displayed a similarly high reproductive rate (&gt;3) but a lower fatality rate [<xref ref-type="bibr" rid="R3">3</xref>]. COVID-19 has by far the lowest mortality rate of the three and also the highest estimated reproductive rate, which may explain why it is the only one of the three viruses to cause a global pandemic.</p>
<p id="P5">The clinical manifestations caused by the three viruses are similar. They all affect the lungs and provoke extensive alveolar damage [<xref ref-type="bibr" rid="R2">2</xref>]. However, while patients affected with SARS or MERS almost always developed a fever and also presented a high number of cases with gastrointestinal symptoms, patients with COVID-19 rarely develop gastrointestinal symptoms. Furthermore, the majority of COVID-19 patients are either asymptomatic or present mild symptoms, a factor that has played a role in the spread of the disease [<xref ref-type="bibr" rid="R3">3</xref>]. Thrombosis and embolisms have been observed both in SARS and COVID-19 patients [<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>] and may explain sudden deaths observed in recovering patients.</p>
<p id="P6">All three infections have been associated with a cytokine storm triggered by an excessively stimulated immune system [<xref ref-type="bibr" rid="R3">3</xref>], which contributes to the morbidity of the diseases in severe patients. This cytokine storm is characterised by the release of large quantities of pro-inflammatory cytokines (such as Interferon-alpha (IFN-alpha), IFN-gamma, Tumor Necrosis Factor alpha (TNF-alpha) and Interleukin 6 (IL-6)) and chemokines, which induce an immune responses that damages internal organs and can result in death [<xref ref-type="bibr" rid="R11">11</xref>]. Intriguingly, the upregulation of anti-inflammatory cytokines such as IL-4 and IL-10 has also been observed [<xref ref-type="bibr" rid="R12">12</xref>]. The use of cytokine inhibitors may be beneficial after the onset of the cytokine storm. In particular, tocilizumab, an anti-IL-6 receptor monoclonal antibody, has been tested in COVID-19 patients and showed promising results [<xref ref-type="bibr" rid="R13">13</xref>]. Conversely, IFN-beta expression is inhibited by SARS-CoV-1 infections [<xref ref-type="bibr" rid="R14">14</xref>], while a general type I interferon inhibition has been observed in SARS-CoV-2 infections [<xref ref-type="bibr" rid="R15">15</xref>]. Type I interferons have antiviral properties and may be actively repressed by SARS-CoV-1 and SARS-CoV-2 during infection to escape the host immune response. Indeed, a clinical trial with an IFN-beta aerosol indicated a reduction in the number of patients developing critical conditions [<xref ref-type="bibr" rid="R16">16</xref>].</p>
<p id="P7">Various antiviral and anti-inflammatory drugs have been tested for their efficacy against coronavirus infections. Among them, the most prominent ones are: lopinavir/ritonavir, remdesivir, chloroquine [<xref ref-type="bibr" rid="R3">3</xref>], baricitinib, fedratinib, and ruxolitinib [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>]. Trametinib and selumetinib, two ERK/MAPK signal pathway inhibitors, have also shown significant efficacy <italic>in vitro</italic> against MERS-CoV infections [<xref ref-type="bibr" rid="R19">19</xref>].</p>
<p id="P8">These epidemics coincided with the development and rise of large scale gene expression analysis technologies (microarray and later on RNA-seq), with various groups embracing these technologies to generate a plethora of data sets that are currently publicly available.</p>
<p id="P9">For this review, we have selected seven public datasets (six transcriptomes and a proteome) based on cell lines infected with MERS-CoV, SARS-CoV-1 and SARS-CoV-2. While not aiming at providing a comprehensive meta-analysis, we wanted to highlight major similarities and differences both across species and across studies on the same species at the gene expression or proteomic level.</p>
</sec>
<sec id="S2" sec-type="materials | methods">
<title>Materials and methods</title>
<p id="P10">We selected a total of seven studies: six consisted of transcriptomic data (four microarrays, two RNA-seq) and one consisted of proteomic data. Of these studies three were conducted on MERS-CoV, one on SARS-CoV-1, one on SARS-CoV-2 and one on both SARS-CoV-1 and SARS-CoV-2. Datasets were obtained from the Gene Expression Omnibus (GEO) repository, except for the proteomic dataset, which was obtained from the Proteomics Identification Database (PRIDE). Details on each dataset are provided in <xref ref-type="table" rid="T1">Table 1</xref>. Where available we used the read or LC-MS/MS spectral counts produced by the authors, otherwise we generated read counts from the raw fastq files with the Salmon software [<xref ref-type="bibr" rid="R20">20</xref>].</p>
<p id="P11">For the analysis presented here, only measurements taken 24h or longer post-infection were considered. For the GSE65574 dataset, only the infection with the wildtype MERS virus was considered. In total, the analysed samples consisted of five samples infected with MERS-CoV, eleven samples infected with SARS-CoV-1 and seven samples (including the proteome dataset) infected with SARS-CoV-2. The filtered read counts were then analysed with VirOmics Playground, a cloud-based open access bioinformatics interface based on a platform that we developed for the analysis and visualisation of transcriptomic and proteomic data [<xref ref-type="bibr" rid="R26">26</xref>].</p>
<p id="P12">Unless otherwise stated, significant differential expression (q&lt;0.05) was calculated using the intersection between three algorithms, namely edgeR, DEseq2 and limma [<xref ref-type="bibr" rid="R27">27</xref>–<xref ref-type="bibr" rid="R29">29</xref>], and with a minimum logFC of 0.5. The same approach was also used when identifying significantly altered KEGG pathways, when performing a drug connectivity analysis or when performing a word cloud analysis, with the three algorithms being camera, GSVA and fGSEA [<xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R32">32</xref>].</p>
<p id="P13">Discovery of pathways with altered expression for the proteomic data was performed via an enrichment analysis of keywords in reference datasets (displayed as a world cloud), since the KEGG pathway analysis with combined algorithms did not yield significant results. More information on the methods used can be found both in Akhmedov et al [<xref ref-type="bibr" rid="R26">26</xref>] and on the online documentation (<ext-link ext-link-type="uri" xlink:href="https://omicsplayground.readthedocs.io/en/latest/">https://omicsplayground.readthedocs.io/en/latest/</ext-link>).</p>
<p id="P14">The L1000 Connectivity Map database [<xref ref-type="bibr" rid="R33">33</xref>] was accessed via the platform to identify common inhibitory drug mode of actions against all three viral species, as described in Akhmedov et al [<xref ref-type="bibr" rid="R26">26</xref>].</p>
<p id="P15">Venn diagrams of the KEGG pathways comparisons were generated with an online tool (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.psb.ugent.be/webtools/Venn/">http://bioinformatics.psb.ugent.be/webtools/Venn/</ext-link>).</p>
</sec>
<sec id="S3" sec-type="results">
<title>Results</title>
<sec id="S4">
<title>Differentially Expressed Genes</title>
<p id="P16">The numbers of differentially expressed genes (or proteins) varied greatly across studies. While the numbers were fairly similar across the three MERS datasets, great variations were observed in both the SARS-CoV-1 and SARS-CoV-2 datasets (<xref ref-type="table" rid="T2">Table 2</xref>). Thus, for example, the number of differentially expressed genes in the SARS-CoV-2 datasets (excluding the H1299 cell line that yielded no dysregulated genes) ranged from 55 for the GSE147507 A459 cell line to 4425 for the GSE148729 Calu-3 cell line. This could be a reflection of the different cell lines, infection protocols and possibly viral strains used in the studies. It was also observed that the H1299 cell line (potentially a typical host cell for SARS viruses) did not show any evidence of gene expression alterations. This could be due to a failure in the infection protocol.</p>
<p id="P17">In the only experiment where the same cell lines were infected with SARS-CoV-1 and SARS-CoV-2, there were striking differences in the amount of differentially expressed genes. Thus, in Caco-2 cells, infections with SARS-CoV-1 generated almost 6x more dysregulated genes compared to an infection with SARS-CoV-2. Meanwhile, the opposite was true in Calu-3 cells, where a SARS-CoV-2 infection generated more than 2X differentially expressed genes compared to a SARS-CoV-1 infection. Given the genetic similarity between the two viruses, such differences are rather unexpected.</p>
<p id="P18">When looking at the top 10 up- and down-regulated genes in each sample split by virus (excluding samples consisting of H1299 infected cells), no shared downregulated genes could be observed across virus species. However, MERS-CoV infected cells all shared the same most upregulated gene (SSX2), independently of time of collection or cell type. Furthermore, gene SLC22A23 was identified among the top 10 upregulated genes in all the samples collected 24h post infection. Gene FBXL8 (F-box and leucine rich repeat protein 8) was in the top 10 upregulated genes in all samples from datasets GSE65574 and GSE86529 and was also significantly upregulated in dataset GSE45042. Gene HSPA6 was in the top 10 upregulated genes of all the GSE86529 samples and was also significantly upregulated in the samples from the other two datasets.</p>
<p id="P19">For SARS-CoV-1 infected Calu-3 cells, IL-6 was among the top 10 upregulated genes across various time points in both available studies. For SARS-CoV-2 infected cells, no shared upregulated genes could be found. Considering that all available samples were from a different cell line each may explain the lack of commonality.</p>
</sec>
<sec id="S5">
<title>Viral spike protein cellular targets and priming protein</title>
<p id="P20">There was no consistent up- or down-regulation of the DPP4 gene (the receptor for the MERS-CoV S protein) across the seven studies (<xref ref-type="fig" rid="F1">Fig 1</xref>-<xref ref-type="fig" rid="F3">3 A-C</xref>). In MERS-infected samples, the gene was significantly upregulated in study GSE45042 and non-significantly in study GSE65574 (<xref ref-type="fig" rid="F1">Fig 1A and 1B</xref>), but downregulated in study GSE86529 (<xref ref-type="fig" rid="F1">Fig 1C</xref>). One SARS-CoV study (GSE148729) conversely indicated down-regulation in Calu-3 cells and, in the case of SARS-CoV-1, Caco-2 cells (<xref ref-type="fig" rid="F2">Fig 2B</xref> and <xref ref-type="fig" rid="F3">3A</xref>). There was no statistically significant change in expression in other SARS-CoV infected samples.</p>
<p id="P21">The expression of the ACE2 gene, whose product serves as a receptor for the SARS-CoV-1/2 S protein, was unaltered in MERS infected cell lines (<xref ref-type="fig" rid="F1">Fig 1D-F</xref>). The picture was more mixed in SARS-CoV-1/2 infected cell lines. There was no evidence of gene expression reduction in Calu-3 cells infected with SARS-CoV-1 (<xref ref-type="fig" rid="F2">Fig 2C</xref>) or NHBE and A459 cells infected with SARS-CoV-2 (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). Even at the proteome level, no difference in expression was detected (<xref ref-type="fig" rid="F3">Fig 3F</xref>). Only in one study, infection with both SARS-CoV species induced a statistically significant reduction in gene expression, but only in one of the three cell lines that were infected, namely Calu-3 (<xref ref-type="fig" rid="F2">Fig 2D</xref> and <xref ref-type="fig" rid="F3">3B</xref>).</p>
<p id="P22">Finally, TMPRSS2 gene expression provided very mixed results. It was observed to be either down-regulated (<xref ref-type="fig" rid="F1">Fig 1G</xref>), up-regulated (<xref ref-type="fig" rid="F1">Fig 1I</xref>) or unaltered (<xref ref-type="fig" rid="F1">Fig 1H</xref>) in MERS-infected cell lines. Expression was down-regulated in Calu-3 cells infected with either SARS-CoV-1 or SARS-CoV-2 (<xref ref-type="fig" rid="F2">Fig 2F</xref> and <xref ref-type="fig" rid="F3">3G</xref>), but was otherwise unaffected in all other samples. No data was available from the proteome study.</p>
</sec>
<sec id="S6">
<title>Immune Response Genes</title>
<p id="P23">Coronavirus infections have been associated with the increased expression of various cytokines. Fifteen cytokines selected based on the available literature was selected for analysis across any of the available samples collected at least 24h post infection, excluding the proteomic dataset as none of the cytokines were present there, and the H1299 cell lines, as there were no dysregulated genes present, for a total of 18 samples.</p>
<p id="P24">Of these cytokines, seven were found to be upregulated in at least one sample for each of the three species, namely: IL-1B, IL-6, IL-8, IL-12A, CXCL10 (C-X-C motif chemokine ligand 10), CCL2 (Chemokine C-C ligand 2) and TNF-alpha (<xref ref-type="fig" rid="F4">Fig. 4</xref>). IL-6, and to a lesser extent IL-8 and CCL2, were frequently upregulated across all three diseases (MERS, SARS and COVID19). IL-7, on the other hand, was the only gene upregulated in SARS and COVID19, but not MERS.</p>
<p id="P25">IFN-beta and IFN-epsilon were the only two type I interferons that were measured in all three SARS and Covid-19 datasets (GSE14707, GSE37827 and GSE148729). There was a complete lack of statistically significant upregulation for IFN-epsilon following infection in any of the datasets at any available time point (<xref ref-type="fig" rid="F5">Figs. 5</xref>-<xref ref-type="fig" rid="F7">7</xref>). While there was a lack of upregulation early on in the infection, fter 24h IFN-beta expression did increase did increase in Calu-3 cells in two of the datasets (<xref ref-type="fig" rid="F5">Fig 5</xref>-<xref ref-type="fig" rid="F6">6</xref>). In the only study where SARS-CoV-2 infections were compared against two other respiratory tract viruses, namely Influenza A virus (IAV) and Respiratory Syncytial Virus (RSV), the difference in type I interferon expression levels was striking.SARS-CoV-2 infections showed expression profile indistinguishable from control samples, in clear contrast with a general upregulation of the same interferons in the infections with IAV or RSV (<xref ref-type="fig" rid="F7">Fig 7E-H</xref>). The picture was less clear in MERS-CoV infected samples, with some showing a slight upregulation and others no change in Type I interferon expression levels (data not shown).</p>
</sec>
<sec id="S7">
<title>Altered Pathway Analysis</title>
<p id="P26">For the six transcriptome studies, a KEGG pathway analysis was performed to identify pathways with significantly (q&lt;0.05) altered expression levels in all samples collected at least 24h post infection. Samples composed of infected H1299 cell lines were excluded, due to the lack of differentially expressed genes. As the KEGG pathway analysis yielded no significant results for the proteome dataset, its protein expression pattern was compared against a collection of more than 50,000 genesets contained within the platform [<xref ref-type="bibr" rid="R26">26</xref>] and a word cloud plot based on the results was generated.</p>
<p id="P27">The word cloud plot (<xref ref-type="fig" rid="F8">Fig 8</xref>) contained terms that have been described in the published article based on the same dataset [<xref ref-type="bibr" rid="R25">25</xref>]. Thus, the term “cholesterol” appears with a negative normalised enrichment score (NES), indicating a downregulation of associated genes. Conversely, genes in keywords associated with carbon metabolism (glycolysis, glucose) were upregulated. A slight upregulation of the spliceosome KEGG pathway could be observed, although it was not statistically significant (data not shown).</p>
<p id="P28">Comparing the various samples across studies is not obvious, because of the different conditions (viral species, time of collections, cell lines and infection protocols). The results of the various datasets were thus combined in two ways. First of all, only the samples collected 24h post infection were considered. The resulting differentially expressed pathways (<xref ref-type="supplementary-material" rid="SD1">Table S1-S3</xref>) were split into up- and down-regulated groups and combined by species and intersections between the three species displayed as Venn diagrams. Secondly, only experiments conducted on Calu-3 cells (the most common cell used in the studies selected here) were chosen, but including any samples collected between 24h and 72h post infection. The up- and down-regulated KEGG pathways (<xref ref-type="supplementary-material" rid="SD1">Table S4-S6</xref>) were again combined by species, and Venn diagrams were produced as indicated above.</p>
<p id="P29">The 24h samples intersection of KEGG pathways yielded three upregulated pathways and six downregulated that were shared by all three species (<xref ref-type="fig" rid="F9">Fig 9</xref>-<xref ref-type="fig" rid="F10">10</xref>), while two and eight were shared between SARS-CoV-1 and SARS-CoV-2 infected samples respectively (<xref ref-type="fig" rid="F9">Fig 9</xref>-<xref ref-type="fig" rid="F10">10</xref>). The upregulated pathways shared by all three species included terms related to immunity and ribosome formation, while downregulated pathways included the “Valine, Leucine and Isoleucine degradation” pathway, “pyruvate metabolism” and the “peroxisome” pathway (<xref ref-type="table" rid="T3">Table 3</xref>). The “complement and coagulation” pathway was among the upregulated pathways in common between SARS-CoV-1 and SARS-CoV-2 infected cells, while shared downregulated pathways included the “glycolysis and gluconeogenesis” pathway (<xref ref-type="table" rid="T4">Table 4</xref>).</p>
<p id="P30">The intersection analysis based on Calu-3 cells, yielded 1 upregulated and 6 downregulated KEGG pathways shared between all viral species and 14 and 22 respectively shared between cells infected with SARS-CoV-1 and SARS-CoV-2 (<xref ref-type="fig" rid="F11">Fig 11</xref>-<xref ref-type="fig" rid="F12">12</xref>). The list of pathways shared by all three species included the “cytokine cytokine receptor” pathway, as well as pathways related to carbohydrate metabolism and protection from oxidation (<xref ref-type="table" rid="T5">Table 5</xref>). When comparing SARS-CoV-1 and SARS-CoV-2 infected Calu-3 cells, shared upregulated pathways included different immune-related gene sets, while shared carbohydrate metabolism-related pathways and butanoate metabolism were present among the downregulated pathways (<xref ref-type="table" rid="T6">Table 6</xref>).</p>
</sec>
<sec id="S8">
<title>Drug Connectivity Map Analysis</title>
<p id="P31">A Drug Connectivity analysis was performed on a total of five MERS-CoV infected samples, 9 SARS-CoV-1 infected samples and five SARS-CoV-2 infected samples (including the proteome study). Drug gene sets that had statistically significant inversely correlated expression profiles to the experimental results were obtained and summarised by mechanisms of action through our platform. The top 10 most negatively correlated mechanisms were then combined by disease (MERS, SARS or COVID-19).</p>
<p id="P32">Samples infected by MERS-CoV displayed a strong negative correlation with cyclin dependant kinase (CDK), epidermal growth factor receptor (EGFR), dual specificity mitogen-activated protein kinase (MEK), mammalian target of rapamycin (mTOR), phosphatidylinositol-3 kinases (PI3K) and tyrosine-protein kinase src (src) inhibitors, with at least 4 out of 5 samples showing a negative correlation with such mechanisms of action (<xref ref-type="fig" rid="F13">Fig 13</xref>).</p>
<p id="P33">SARS-CoV-1 infected samples also showed a strong negative correlation (with detection among the top 10 inhibitory profiles in at least 7/9 samples) with CDK, EGFR, MEK and src inhibitors (<xref ref-type="fig" rid="F14">Fig 14</xref>). Additionally, p38 MAPK inhibitors were also prominently represented.</p>
<p id="P34">SARS-CoV-2 infected samples displayed five mechanisms of action with inhibitory potential in at least three of the five samples analysed. These included CDK, EGFR, MEK and src inhibitors, as well as serotonin receptor antagonists, p38 MAPK inhibitors and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) inhibitors (<xref ref-type="fig" rid="F15">Fig 15</xref>).</p>
<p id="P35">Overall, strong support for four mechanisms of action with broad anti-coronavirus inhibitory potential could be detected, namely: CDK, EGFR, MEK and src inhibitors.</p>
<p id="P36">Additionally, p38 MAPK inhibitors were also highly frequently negatively correlated with the gene expression profiles generated by SARS-CoV-1 and SARS-CoV-2 infections, while also being identified as potential inhibitors in three out of five MERS-CoV infected samples.</p>
</sec>
</sec>
<sec id="S9" sec-type="discussion">
<title>Discussion</title>
<sec id="S10">
<title>Gene expression results</title>
<p id="P37">The number of differentially expressed genes varied greatly between samples, even when those were restricted only to samples collected at least 24h after infection. Indeed, the range could vary from 0 to almost 9000 genes. Even when keeping time point, species and host cell lines constant, as in the case of datasets GSE148729 and GSE37827, the number of differentially expressed genes ranged from 72 to 1835. Despite these differences, when clustering studies either by viral species or by host cell line, some macrotrends could be observed at the individual gene level.</p>
<p id="P38">An analysis of the expression of host genes or proteins involved in viral invasion (namely DPP4, ACE2 and TMPRSS2) provided a rather mixed picture. DPP4 appeared to be upregulated in Calu-3 cells, but downregulated in human fibroblasts (<xref ref-type="fig" rid="F1">Fig 1A</xref>-<xref ref-type="fig" rid="F3">3A</xref>). As a modulation of DPP4 by MERS viruses has not been implicated in any phenotypes, the actual biological significance of these observations or whether they represent a stochastic effect due to study setups, remains to be determined.</p>
<p id="P39">Conversely, ACE2 downregulation by the virus has been implicated in the pathology of SARS-CoV-1 [<xref ref-type="bibr" rid="R8">8</xref>] and potentially SARS-CoV-2 [<xref ref-type="bibr" rid="R34">34</xref>]. As expected, no alteration in expression was observed in MERS-infected cells. However, in SARS-CoV-1 and SARS-CoV-2 infected cells, a statistically significant downregulation of the gene could be observed only in one study and one cell line (Calu-3). Furthermore, in another study where Calu-3 cells were infected with SARS-CoV-1 (GSE37827), no significant downregulation was detectable (<xref ref-type="fig" rid="F4">Fig 4B</xref>). There was no evidence of downregulation at the protein level either. Again, the discrepancies could be due to the many variables that separate each dataset. But it is also possible that ACE2 downregulation may only occur in certain cells <italic>in vivo</italic>, and requires an interaction with the host immune system <italic>in vivo</italic>. Alternatively, it could also be that the mouse model used to generate the original observation may not be a reliable model for human infections.</p>
<p id="P40">TMPRSS2 gene expression also provided a very mixed picture, with MERS studies showing both upregulation, downregulation and no difference, while in studies involving SARS-CoV-1 and SARS-CoV-2, a downregulation could be observed in Calu-3 cells only. Again, this may be more a reflection of the differences between studies than any biological significance.</p>
<p id="P41">Several cytokines have been implicated in the pathology caused by coronavirus infections. 15 of these were selected based on evidence in the literature and analysed for changes in expression at the gene level following viral infection. In the 6 transcriptomic studies, we found evidence for the significant upregulation of seven of these cytokines (namely IL-1B, IL-6, IL-8, IL-12A, CXCL10, CCL2 and TNF-alpha.) in at least a sample group per species. This is consistent with the theory of a “cytokine storm” occurring during coronavirus infections. On the other hand, there was a general lack of induction of type I interferons in SARS-CoV-1 and SARS-CoV-2 infections, particularly early on in the infection, consistent with observations that both viruses can interfere with the expression of these antiviral cytokines.</p>
</sec>
<sec id="S11">
<title>Altered Pathway Analysis</title>
<p id="P42">Analysis of the proteome of cells infected with SARS-CoV-2 confirmed that the cholesterol pathway was downregulated, whereas carbon metabolism was upregulated, as described in the study by Bojkova et al [<xref ref-type="bibr" rid="R25">25</xref>]. No significant upregulation of the spliceosome could be observed, although this was most likely due to the more stringent analysis performed by the platform compared to traditional approaches for proteome analysis.</p>
<p id="P43">When looking at the transcriptome samples collected 24h post-infection, irrespective of cell-line, the upregulation of two KEGG pathways associated with immune responses was observed in all three viruses, as well as the upregulation of the “Ribosome biogenesis” pathway. The former two are expected as the results of defensive mechanisms against viral infections.The latter could be a consequence of the postulated disruption of ribosome biogenesis by the viral N protein [<xref ref-type="bibr" rid="R35">35</xref>]. The “propanoate metabolism” and “pyruvate metabolism” pathways were both downregulated in all three viruses and as they are both involved in carbohydrate metabolism, were in contrast with the findings from the proteome analysis. Conversely, the inhibition of the “peroxisome pathway” might reflect a direct exploitation by coronaviruses [<xref ref-type="bibr" rid="R36">36</xref>]. As the peroxisome also plays a role in cholesterol biosynthesis [<xref ref-type="bibr" rid="R37">37</xref>], this observation is consistent with the proteome data. When focusing only on the two SARS-CoV species, another pathway related to immune responses (“complement and coagulation cascades”) was upregulated in both species, while pathways related to carbohydrate metabolism were again downregulated. Additionally amino acid synthesis and drug metabolic pathways were also under-expressed in both viral species. Intriguingly, the disruption of the cytochrome P450 metabolic machinery in COVID-19 patients has been previously hypothesised [<xref ref-type="bibr" rid="R38">38</xref>].</p>
<p id="P44">Focusing the KEGG pathway analysis on samples with infected Calu-3 cells highlighted once more the upregulation of the “cytokine cytokine receptor” pathway in all three viral species. Several pathways were also downregulated in all three species. The downregulation of the “Lysosome” pathway may reflect the dependence of coronavirus cell entry on the lysosomal pathway [<xref ref-type="bibr" rid="R39">39</xref>]. Downregulation of the pyruvate pathway was related to the general inhibition of carbohydrate metabolism observed in the 24h samples. Finally, the downregulation of glutathione metabolism could reflect a direct viral manipulation of host defense mechanisms. Influenza infections have been associated with depletion of glutathione levels, which may favor viral replication [<xref ref-type="bibr" rid="R40">40</xref>]. The largest number of shared dysregulated pathways was observed between SARS-CoV-1 and SARS-CoV-2 infected Calu-3 cells. Besides immunity and cell stress related terms, upregulated pathways also highlighted the similarity with other viral diseases (<xref ref-type="table" rid="T6">Table 6</xref>). Pathways related to carbohydrate metabolisms were once more downregulated, highlighting the contrast between proteomic and transcriptomic datasets. The downregulation of the peroxisome pathway is consistent with glutathione inhibition, due to the role of the organelle in both the metabolism of reactive oxygen species and its antiviral properties [<xref ref-type="bibr" rid="R41">41</xref>]. The inhibition of the “butanoate metabolism” pathway could also fit this general trend of viral-mediated modulation of the immune system, due to its role in immune homeostasis [<xref ref-type="bibr" rid="R42">42</xref>].</p>
</sec>
<sec id="S12">
<title>Drug Connectivity Map Analysis</title>
<p id="P45">Four main mechanisms of action (CDK, EGFR, MEK and src inhibitors) with broad inhibitory potential against human coronavirus infections were postulated across most of the datasets. An additional mechanism (p38 MAPK inhibitors) was also suggested when focusing on SARS-CoV-1 and SARS-CoV-2 infections. All these inhibitory mechanisms target kinases and indeed kinase inhibitors have been proposed as broad-spectrum antiviral therapies [<xref ref-type="bibr" rid="R43">43</xref>]. When looking at individual drugs that were identified as having anti-coronavirus properties by the bioinformatic platform, the MEK-inhibitor trametinib had already shown inhibitory potential against MERS-CoV infections [<xref ref-type="bibr" rid="R44">44</xref>]. Furthermore, various key cellular signaling pathways critical for SARS-CoV-2 infection have been identified [<xref ref-type="bibr" rid="R45">45</xref>]. These included the mTOR-PI3K-AKT and ABL-BCR/MAPK pathways, inhibitors against which also appeared in our analysis (<xref ref-type="fig" rid="F12">Fig 12</xref>).</p>
</sec>
</sec>
<sec id="S13" sec-type="conclusions">
<title>Conclusion</title>
<p id="P46">Comparing gene expression coronavirus infection datasets across <italic>in vitro</italic> studies is fraught with potential pitfalls, due to the many variables that can alter the outcome of a study (such as viral strains used, infection protocols, cell lines used, time points of collection, sequencing technologies,etc..). Nonetheless, such information can provide some general insights on shared coronavirus infection features that can help discern potential targets for intervention and provide a better understanding of viral biology.</p>
<p id="P47">In this article, we observed several patterns shared across coronavirus species that were consistent with coronavirus biology and pathology. However, we also observed contrasting results (e.g. the expression of the ACE2 gene or regulation of the carbohydrate metabolism) that highlight the difficulty of working with heterogeneous datasets.</p>
<p id="P48">We could also identify shared potential mechanisms of viral inhibition that reflect what is known from the literature and further strengthen the argument for the selection of drugs that can be repurposed to treat coronavirus infections.</p>
<p id="P49">As a final note, all the datasets and analysis tools are currently available online (<ext-link ext-link-type="uri" xlink:href="https://public.bigomics.ch/app/omicsplayground_viromics">https://public.bigomics.ch/app/omicsplayground_viromics</ext-link>) and can be accessed to repeat and verify the analysis performed in this article.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Materials</label>
<media xlink:href="EMS96410-supplement-Supplementary_Materials.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66380" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Supporting information</label>
<media xlink:href="EMS96410-supplement-Supporting_information.pdf" mimetype="application" mime-subtype="pdf" id="N66389" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title>
<source>Methods Mol Biol</source>
<year>2015</year>
<volume>1282</volume>
<fpage>1</fpage>
<lpage>23</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guarner</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Three Emerging Coronaviruses in Two Decades</article-title>
<source>Am J Clin Pathol</source>
<year>2020</year>
<volume>153</volume>
<issue>4</issue>
<fpage>420</fpage>
<lpage>421</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Insight into 2019 novel coronavirus – An updated interim review and lessons from SARS-CoV and MERS-CoV</article-title>
<source>Int J Infect Dis</source>
<year>2020</year>
<volume>94</volume>
<fpage>119</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10224</issue>
<fpage>565</fpage>
<lpage>574</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Mou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>SL</given-names>
</name>
<etal/>
</person-group>
<article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>
<source>Nature</source>
<year>2013</year>
<volume>495</volume>
<issue>7440</issue>
<fpage>251</fpage>
<lpage>254</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Hiscox</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>NM</given-names>
</name>
</person-group>
<article-title>ACE2: from vasopeptidase to SARS virus receptor</article-title>
<source>Trends Pharmacol Sci</source>
<year>2004</year>
<volume>25</volume>
<issue>6</issue>
<fpage>291</fpage>
<lpage>294</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kleine-Weber</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>2</issue>
<fpage>271</fpage>
<lpage>280</lpage>
<elocation-id>e8</elocation-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuba</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Imai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title>
<source>Nat Med</source>
<year>2005</year>
<volume>11</volume>
<issue>8</issue>
<fpage>875</fpage>
<lpage>879</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang-Hua</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Le-Min</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ai-Bin</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Severe acute respiratory syndrome and venous thromboembolism in multiple organs</article-title>
<source>Am J Respir Crit Care Med</source>
<year>2010</year>
<volume>182</volume>
<issue>3</issue>
<fpage>436</fpage>
<lpage>437</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodigiani</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Iapichino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carenzo</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy</article-title>
<source>Thromb Res</source>
<year>2020</year>
<volume>191</volume>
<fpage>9</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coperchini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chiovato</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Magri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rotondi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system</article-title>
<source>Cytokine Growth Factor Rev</source>
<year>2020</year>
<volume>53</volume>
<fpage>25</fpage>
<lpage>32</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10223</issue>
<fpage>497</fpage>
<lpage>506</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2020</year>
<volume>117</volume>
<issue>20</issue>
<fpage>10970</fpage>
<lpage>10975</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spiegel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pichlmair</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mart´ınez-Sobrido</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<issue>4</issue>
<fpage>2079</fpage>
<lpage>2086</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acharya</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gack</surname>
<given-names>MU</given-names>
</name>
</person-group>
<article-title>Dysregulation of type I interferon responses in COVID-19</article-title>
<source>Nat Rev Immunol</source>
<year>2020</year>
<volume>20</volume>
<issue>7</issue>
<fpage>397</fpage>
<lpage>398</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monk</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tear</surname>
<given-names>VJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title>
<source>Lancet Respir Med</source>
<year>2021</year>
<volume>9</volume>
<issue>2</issue>
<fpage>196</fpage>
<lpage>206</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richardson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tucker</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>395</volume>
<issue>10223</issue>
<fpage>e30</fpage>
<lpage>e31</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stebbing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Phelan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<issue>4</issue>
<fpage>400</fpage>
<lpage>402</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kindrachuk</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies</article-title>
<source>Drugs</source>
<year>2017</year>
<volume>77</volume>
<issue>18</issue>
<fpage>1935</fpage>
<lpage>1966</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duggal</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Kingsford</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title>
<source>Nat Methods</source>
<year>2017</year>
<volume>14</volume>
<issue>4</issue>
<fpage>417</fpage>
<lpage>419</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josset</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Agnihothram</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus</article-title>
<source>mBio</source>
<year>2013</year>
<volume>4</volume>
<issue>3</issue>
<fpage>e00165</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Eisfeld</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sch૤fer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Josset</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses</article-title>
<source>mBio</source>
<year>2014</year>
<volume>5</volume>
<issue>3</issue>
<fpage>e01174</fpage>
<lpage>14</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>HD</given-names>
</name>
<name>
<surname>Cockrell</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Gralinski</surname>
<given-names>LE</given-names>
</name>
<etal/>
</person-group>
<article-title>MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis</article-title>
<source>mBio</source>
<year>2017</year>
<volume>8</volume>
<issue>4</issue>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanco-Melo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nilsson-Payant</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<issue>5</issue>
<fpage>1036</fpage>
<lpage>1045</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bojkova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Proteomics of SARS-CoV-2-infected host cells reveals therapy targets</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<issue>7816</issue>
<fpage>469</fpage>
<lpage>472</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akhmedov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Geiger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kwee</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Omics Playground: a comprehensive self-service platform for visualization, analytics and exploration of Big Omics Data</article-title>
<source>NAR Genomics and Bioinformatics</source>
<year>2020</year>
<volume>2</volume>
<issue>1</issue>
<elocation-id>lqz019</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>
<source>Bioinformatics</source>
<year>2010</year>
<volume>26</volume>
<issue>1</issue>
<fpage>139</fpage>
<lpage>140</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Love</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Huber</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Anders</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>
<source>Genome Biology</source>
<year>2014</year>
<volume>15</volume>
<fpage>550</fpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Phipson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
<source>Nucleic Acids Research</source>
<year>2015</year>
<volume>43</volume>
<issue>7</issue>
<elocation-id>e47</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</name>
</person-group>
<article-title>Camera: a competitive gene set test accounting for inter-gene correlation</article-title>
<source>Nucleic Acids Res</source>
<year>2012</year>
<volume>40</volume>
<issue>17</issue>
<elocation-id>e133</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hänzelmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Castelo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Guinney</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>GSVA: gene set variation analysis for microarray and RNA-seq data</article-title>
<source>BMC Bioinformatics</source>
<year>2013</year>
<volume>14</volume>
<fpage>7</fpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korotkevich</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sukhov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sergushichev</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Fast gene set enrichment analysis</article-title>
<source>bioRxiv</source>
<year>2019</year>
<pub-id pub-id-type="doi">10.1101/060012</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subramanian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Narayan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Corsello</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>
<article-title>A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles</article-title>
<source>Cell</source>
<year>2017</year>
<volume>171</volume>
<issue>6</issue>
<fpage>1437</fpage>
<lpage>1452</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudry</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lavandero</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>Manipulation of ACE2 expression in COVID-19</article-title>
<source>Open Heart</source>
<year>2020</year>
<volume>7</volume>
<issue>2</issue>
<elocation-id>e001424</elocation-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wurm</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hiscox</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell</article-title>
<source>J Virol</source>
<year>2002</year>
<volume>76</volume>
<issue>10</issue>
<fpage>5233</fpage>
<lpage>5250</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazarow</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Viruses exploiting peroxisomes</article-title>
<source>Curr Opin Microbiol</source>
<year>2011</year>
<volume>14</volume>
<issue>4</issue>
<fpage>458</fpage>
<lpage>469</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krisans</surname>
<given-names>SK</given-names>
</name>
</person-group>
<article-title>The role of peroxisomes in cholesterol metabolism</article-title>
<source>Am J Respir Cell Mol Biol</source>
<year>1992</year>
<volume>7</volume>
<issue>4</issue>
<fpage>358</fpage>
<lpage>364</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ghiaty</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Shoieb</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>El-Kadi</surname>
<given-names>AOS</given-names>
</name>
</person-group>
<article-title>Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms</article-title>
<source>Med Hypotheses</source>
<year>2020</year>
<volume>144</volume>
<elocation-id>110033</elocation-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burkard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Verheije</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Wicht</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>
<article-title>Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner</article-title>
<source>PLoS Pathog</source>
<year>2014</year>
<volume>10</volume>
<issue>11</issue>
<elocation-id>e1004502</elocation-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghezzi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Role of glutathione in immunity and inflammation in the lung</article-title>
<source>Int J Gen Med</source>
<year>2011</year>
<volume>4</volume>
<fpage>105</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixit</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Boulant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Peroxisomes are signaling platforms for antiviral innate immunity</article-title>
<source>Cell</source>
<year>2010</year>
<volume>141</volume>
<issue>4</issue>
<fpage>668</fpage>
<lpage>681</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Butyrate: A Double-Edged Sword for Health?</article-title>
<source>Adv Nutr</source>
<year>2018</year>
<volume>9</volume>
<issue>1</issue>
<fpage>21</fpage>
<lpage>29</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schor</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Einav</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</article-title>
<source>DNA Cell Biol</source>
<year>2018</year>
<volume>37</volume>
<issue>2</issue>
<fpage>63</fpage>
<lpage>69</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kindrachuk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ork</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>BJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2015</year>
<volume>59</volume>
<issue>2</issue>
<fpage>1088</fpage>
<lpage>1099</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ramaiah</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Antiviral Drug Screen of Kinase inhibitors Identifies Cellular Signaling Pathways Critical for SARS-CoV-2 Replication</article-title>
<source>BioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.06.24.150326</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig 1</label>
<caption>
<title>Expression levels in MERS-CoV infected cells</title>
<p>Expression levels for genes DPP4, ACE2 and TMPRSS2 per sample groups expressed in logCPM (count per million) from the three MERS-CoV infected datasets. A,D,G: GSE45042; B,E,H: GSE65574; C,F,I: GSE86529.</p>
</caption>
<graphic xlink:href="EMS96410-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig 2</label>
<caption>
<title>Expression levels in SARS-CoV-1 infected cells.</title>
<p>Expression levels for genes DPP4, ACE2 and TMPRSS2 per sample groups expressed in logCPM (count per million) from two SARS-CoV-1 infected datasets. A,C,E: GSE37827; B,D,F: GSE148729.</p>
</caption>
<graphic xlink:href="EMS96410-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig 3</label>
<caption>
<title>Expression levels in SARS-CoV-2 infected cells.</title>
<p>Expression levels for genes DPP4, ACE2 and TMPRSS2 per sample groups expressed in logCPM (count per million) from three SARS-CoV-2 infected datasets. A,D,G: GSE147507; B,E,H: GSE148729.; C,F: proteome.</p>
</caption>
<graphic xlink:href="EMS96410-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig 4</label>
<caption>
<title>Upregulated cytokines.</title>
<p>Instances of significantly upregulated cytokines in any sample collected 24h or more post infection, divided by disease.</p>
</caption>
<graphic xlink:href="EMS96410-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig 5</label>
<caption>
<title>Type I interferon gene expression in samples infected with SARS-CoV-1 from study GSE37827.</title>
<p>A: IFN-beta expression in Calu-3 cells 12h post-infection; B: IFN-beta expression in Calu-3 cells 24h post-infection; C: IFN-beta expression in Calu-3 cells 48h post-infection; D: IFN-epsilon expression in Calu-3 cells 12h post-infection; E: IFN-epsilon expression in Calu-3 cells 24h post-infection; F: IFN-epsilon expression in Calu-3 cells 48h post-infection.</p>
</caption>
<graphic xlink:href="EMS96410-f005"/>
</fig>
<fig id="F6" position="float">
<label>Fig 6</label>
<caption>
<title>Type I interferon gene expression in samples infected with SARS-CoV-1 and SARS-CoV-2 from study GSE148729.</title>
<p>A: IFN-alpha-8 expression in Calu-3 cells; B: IFN-beta expression in Calu-3 cells; C: IFN-epsilon expression in Calu-3 cells; D: IFN-alpha-8 expression in Caco-2 cells; E: IFN-beta expression in Caco-2 cells; F: IFN-epsilon expression in Caco-2 cells.</p>
</caption>
<graphic xlink:href="EMS96410-f006"/>
</fig>
<fig id="F7" position="float">
<label>Fig 7</label>
<caption>
<title>Type I interferon gene expression in samples infected with SARS-CoV-2, RSV and IAV from study GSE147507.</title>
<p>A: IFN-alpha-1 expression in NHBE cells; B: IFN-beta expression in NHBE cells; C: IFN-epsilon expression in NHBE cells; D: IFN-lambda-1 expression in NHBE cells; E: IFN-alpha-1 expression in A459 cells; F: IFN-beta expression in A459 cells; G: IFN-epsilon expression in A459 cells; H: IFN-lambda-1 expression in A459 cells.</p>
</caption>
<graphic xlink:href="EMS96410-f007"/>
</fig>
<fig id="F8" position="float">
<label>Fig 8</label>
<caption>
<title>Word cloud plot of the most common keywords in the proteome dataset analysis.</title>
<p>Word cloud plot of the most recurring keywords in the top ranked genesets used to compare the differentially expressed genes appearing 24h post infection in the proteome study [<xref ref-type="bibr" rid="R25">25</xref>].</p>
</caption>
<graphic xlink:href="EMS96410-f008"/>
</fig>
<fig id="F9" position="float">
<label>Fig 9</label>
<caption>
<title>Venn diagram of upregulated pathways 24h post infection.</title>
<p>Venn diagram representation of the intersection between upregulated pathways for infected samples collected 24h after infections.</p>
</caption>
<graphic xlink:href="EMS96410-f009"/>
</fig>
<fig id="F10" position="float">
<label>Fig 10</label>
<caption>
<title>Venn diagram of downregulated pathways 24h post infection.</title>
<p>Venn diagram representation of the intersection between downregulated pathways for infected samples collected 24h after infections.</p>
</caption>
<graphic xlink:href="EMS96410-f010"/>
</fig>
<fig id="F11" position="float">
<label>Fig 11</label>
<caption>
<title>Venn diagram of upregulated pathways in infected Calu-3 cells 24h post infection.</title>
<p>Venn diagram representation of the intersection between upregulated pathways for infected samples collected from Calu-3 infected cells.</p>
</caption>
<graphic xlink:href="EMS96410-f011"/>
</fig>
<fig id="F12" position="float">
<label>Fig 12</label>
<caption>
<title>Venn diagram of downregulated pathways in infected Calu-3 cells 24h post infection.</title>
<p>Venn diagram representation of the intersection between downregulated pathways for infected samples collected from Calu-3 infected cells.</p>
</caption>
<graphic xlink:href="EMS96410-f012"/>
</fig>
<fig id="F13" position="float">
<label>Fig 13</label>
<caption>
<title>Anti-MERS-CoV inhibitory mechanisms.</title>
<p>Cumulative counts of the most significant potential inhibitory mechanisms against MERS-CoV infections in five separate samples.</p>
</caption>
<graphic xlink:href="EMS96410-f013"/>
</fig>
<fig id="F14" position="float">
<label>Fig 14</label>
<caption>
<title>Anti-SARS-CoV-1 inhibitory mechanisms.</title>
<p>Cumulative counts of the most significant potential inhibitory mechanisms against SARS-CoV-1 infections in nine separate samples.</p>
</caption>
<graphic xlink:href="EMS96410-f014"/>
</fig>
<fig id="F15" position="float">
<label>Fig 15</label>
<caption>
<title>Anti-SARS-CoV-2 inhibitory mechanisms.</title>
<p>Cumulative counts of the most significant potential inhibitory mechanisms against SARS-CoV-2 infections in five separate samples.</p>
</caption>
<graphic xlink:href="EMS96410-f015"/>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<title>Details of the datasets used in the analysis.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr style="border-bottom: solid thick">
<th align="left" valign="top">GEO/PXD Code</th>
<th align="left" valign="top">Data Type</th>
<th align="left" valign="top">Virus</th>
<th align="left" valign="top">Cell Line</th>
<th align="left" valign="top">Published</th>
</tr>
</thead>
<tbody>
<tr style="border-top: solid thin">
<td align="left" valign="top" style="border-right: solid thick">GSE45042</td>
<td align="left" valign="top">Microarray</td>
<td align="left" valign="top">MERS-CoV</td>
<td align="left" valign="top">Calu-3</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R22">22</xref>]</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE65574</td>
<td align="left" valign="top">Microarray</td>
<td align="left" valign="top">MERS-CoV</td>
<td align="left" valign="top">Calu-3</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="R23">23</xref>]</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE86529</td>
<td align="left" valign="top">Microarray</td>
<td align="left" valign="top">MERS-CoV</td>
<td align="left" valign="top">HF</td>
<td align="left" valign="top">NA</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827</td>
<td align="left" valign="top">Microarray</td>
<td align="left" valign="top">SARS-CoV-1</td>
<td align="left" valign="top">Calu-3</td>
<td align="left" valign="top">NA</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE147507</td>
<td align="left" valign="top">RNA-seq</td>
<td align="left" valign="top">SARS-CoV-2</td>
<td align="left" valign="top">NHBE, A459</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="R24">24</xref>]</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729</td>
<td align="left" valign="top">RNA-seq</td>
<td align="left" valign="top">SARS-CoV-1/2</td>
<td align="left" valign="top">Caco-2,Calu-3,H1299</td>
<td align="left" valign="top">NA</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PXD017710</td>
<td align="left" valign="top">Proteome</td>
<td align="left" valign="top">SARS-CoV-2</td>
<td align="left" valign="top">Caco-2</td>
<td align="left" valign="top">[<xref ref-type="bibr" rid="R25">25</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<p id="P50">Table notes. A459: adenocarcinomic human alveolar basal epithelial cells; Caco-2: Caucasian colon adenocarcinoma; Calu-3: human non-small-cell lung cancer cell; H1299: human non-small cell lung carcinoma cell; HF: human fibroblasts; NHBE: normal bronchial epithelial cells.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<title>Dysregulated genes (or proteins) in the different groups from the selected studies.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr style="border-bottom: solid thick">
<th align="left" valign="top">SAMPLE</th>
<th align="left" valign="top">UP</th>
<th align="left" valign="top">DOWN</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" style="border-right: solid thick">COVID-19 Proteome 24h</td>
<td align="left" valign="top">177</td>
<td align="left" valign="top">261</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE45042 MERS 24h</td>
<td align="left" valign="top">4264</td>
<td align="left" valign="top">4450</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE65574 icMERS 24h</td>
<td align="left" valign="top">3003</td>
<td align="left" valign="top">2905</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE86529 MERS 24h</td>
<td align="left" valign="top">4045</td>
<td align="left" valign="top">4367</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE86529 MERS 36h</td>
<td align="left" valign="top">3330</td>
<td align="left" valign="top">3189</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE86529 MERS 48h</td>
<td align="left" valign="top">3347</td>
<td align="left" valign="top">3290</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 24h</td>
<td align="left" valign="top">51</td>
<td align="left" valign="top">21</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 30h</td>
<td align="left" valign="top">210</td>
<td align="left" valign="top">31</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 36h</td>
<td align="left" valign="top">475</td>
<td align="left" valign="top">95</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 48h</td>
<td align="left" valign="top">1853</td>
<td align="left" valign="top">1808</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 54h</td>
<td align="left" valign="top">1794</td>
<td align="left" valign="top">2031</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 60h</td>
<td align="left" valign="top">1910</td>
<td align="left" valign="top">2256</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE37827 icSARS 72h</td>
<td align="left" valign="top">1677</td>
<td align="left" valign="top">1793</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE147507 COVID-19 A549 24h</td>
<td align="left" valign="top">53</td>
<td align="left" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE147507 COVID-19 NHBE 24h</td>
<td align="left" valign="top">135</td>
<td align="left" valign="top">41</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 SARS H1299 24h</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 COVID-19 H1299 24h</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 SARS H1299 36h</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 COVID-19 H1299 36h</td>
<td align="left" valign="top">0</td>
<td align="left" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 SARS Calu-3</td>
<td align="left" valign="top">879</td>
<td align="left" valign="top">956</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 COVID-19 Calu-3</td>
<td align="left" valign="top">2141</td>
<td align="left" valign="top">2294</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 SARS Caco-2</td>
<td align="left" valign="top">1186</td>
<td align="left" valign="top">1086</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">GSE148729 COVID-19 Caco-2</td>
<td align="left" valign="top">244</td>
<td align="left" valign="top">101</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN2">
<p id="P51">Table notes. The numbers were based on the intersection of three algorithms with logFC &gt;0.5 and q&lt;0.05, except for the proteome dataset where a single algorithm (DEseq2) and a logFC of 0.2 were selected.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<title>KEGG pathways shared between all three species in samples collected 24h post infections.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">KEGG Pathway</th>
<th align="left" valign="top">UP/DOWN Reg.</th>
</tr>
</thead>
<tbody>
<tr style="border-top: solid thick">
<td align="left" valign="top" style="border-right: solid thick">KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:TNF signaling pathway Homo sapiens hsa04668</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Ribosome biogenesis in eukaryotes Homo sapiens hsa03008</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PROPANOATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG OXIDATIVE PHOSPHORYLATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PARKINSONS DISEASE</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG VALINE LEUCINE AND ISOLEUCINE DEGRADATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PYRUVATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PEROXISOME</td>
<td align="left" valign="top">DOWN</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T4" orientation="portrait" position="float">
<label>Table 4</label>
<caption>
<title>KEGG pathways shared between SARS-CoV-1 and SARS-CoV-2 infected cells in samples collected 24h post infections.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">KEGG Pathway</th>
<th align="left" valign="top">UP/DOWN Reg.</th>
</tr>
</thead>
<tbody>
<tr style="border-top: solid thick">
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Osteoclast differentiation Homo sapiens hsa04380</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG COMPLEMENT AND COAGULATION CASCADES</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ASCORBATE AND ALDARATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG GLYCINE SERINE AND THREONINE METABOLISMN</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG DNA REPLICATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PENTOSE AND GLUCURONATE INTERCONVERSIONS</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG GLYCOLYSIS GLUCONEOGENESIS</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG METABOLISM OF XENOBIOTICS BY CYTOCHROME P450</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG DRUG METABOLISM CYTOCHROME P450</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG OOCYTE MEIOSIS</td>
<td align="left" valign="top">DOWN</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T5" orientation="portrait" position="float">
<label>Table 5</label>
<caption>
<title>KEGG pathways shared between all three species in samples collected from Calu-3 infected cells.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">KEGG Pathway</th>
<th align="left" valign="top">UP/DOWN Reg.</th>
</tr>
</thead>
<tbody>
<tr style="border-top: solid thick">
<td align="left" valign="top" style="border-right: solid thick">KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG FATTY ACID METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG LYSOSOME</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG CITRATE CYCLE TCA CYCLE</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG VALINE LEUCINE AND ISOLEUCINE DEGRADATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PYRUVATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG GLUTATHIONE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T6" orientation="portrait" position="float">
<label>Table 6</label>
<caption>
<title>KEGG pathways shared between SARS-CoV-1 and SARS-CoV-2 infected Calu-3 cells.</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">KEGG Pathway</th>
<th align="left" valign="top">UP/DOWN Reg.</th>
</tr>
</thead>
<tbody>
<tr style="border-top: solid thick">
<td align="left" valign="top" style="border-right: solid thick">KC2:KEGG RIG I LIKE RECEPTOR SIGNALING PATHWAY</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG GRAFT VERSUS HOST DISEASE</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Herpes simplex infection Homo sapiens hsa05168</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG TYPE I DIABETES MELLITUS</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG CYTOSOLIC DNA SENSING PATHWAY</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:TNF signaling pathway Homo sapiens hsa0466</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Influenza A Homo sapiens hsa05164</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG JAK STAT SIGNALING PATHWAY</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ANTIGEN PROCESSING AND PRESENTATION</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Staphylococcus aureus infection Homo sapiens hsa05150</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ALLOGRAFT REJECTION</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">PATHWAY:Inflammatory bowel disease (IBD) Homo sapiens hsa05321</td>
<td align="left" valign="top">UP</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PORPHYRIN AND CHLOROPHYLL METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ASCORBATE AND ALDARATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PROPANOATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG FRUCTOSE AND MANNOSE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PENTOSE PHOSPHATE PATHWAY</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ONE CARBON POOL BY FOLATE</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG STARCH AND SUCROSE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG DNA REPLICATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PENTOSE AND GLUCURONATE INTERCONVERSIONS</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG N GLYCAN BIOSYNTHESIS</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG GLYCOLYSIS GLUCONEOGENESISSM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PARKINSONS DISEASE</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG CARDIAC MUSCLE CONTRACTION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG ALZHEIMERS DISEASE</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG OOCYTE MEIOSIS</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PROXIMAL TUBULE BICARBONATE RECLAMATION</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG METABOLISM OF XENOBIOTICS BY CYTOCHROME P450</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG DRUG METABOLISM CYTOCHROME P450</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG PEROXISOME</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG BUTANOATE METABOLISM</td>
<td align="left" valign="top">DOWN</td>
</tr>
<tr>
<td align="left" valign="top" style="border-right: solid thick">C2:KEGG RETINOL METABOLISMM</td>
<td align="left" valign="top">DOWN</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
